Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized selection trial of nal-IRI + 5-fluorouracil/folinic acid versus docetaxel in second-line extra-pulmonary neuroendocrine carcinoma
2017-002453-11Phase 2Unknown
- Sponsor
- The Christie
- Start
- Dec 2017
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in extrapulmonary neuroendocrine carcinoma (EPNEC) comparing Onivyde + 5-fluorouracil + folinic acid with Docetaxel (2 arms). Primary endpoint: 6-month progression-free survival rate. Status: unknown.
02
Drugs
irinotecanfluorouracilfolinic aciddocetaxel
03
Conditions
extrapulmonary neuroendocrine carcinoma (EPNEC)
Beyond the preview
Go deeper on 2017-002453-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002453-11.